Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.

Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.

Lancet. 2011 Feb 5;377(9764):477-86. doi: 10.1016/S0140-6736(10)62050-8. Epub 2011 Jan 20.

PMID:
21255828
2.

Injectable paromomycin for Visceral leishmaniasis in India.

Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.

N Engl J Med. 2007 Jun 21;356(25):2571-81.

3.

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.

Clin Infect Dis. 2008 Oct 15;47(8):1000-6. doi: 10.1086/591972.

PMID:
18781879
4.

Combination therapy for visceral leishmaniasis.

van Griensven J, Boelaert M.

Lancet. 2011 Feb 5;377(9764):443-4. doi: 10.1016/S0140-6736(10)62237-4. Epub 2011 Jan 20. No abstract available.

PMID:
21255829
5.

Single-dose liposomal amphotericin B for visceral leishmaniasis in India.

Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.

N Engl J Med. 2010 Feb 11;362(6):504-12. doi: 10.1056/NEJMoa0903627.

6.

Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.

Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J.

Clin Infect Dis. 2009 Sep 15;49(6):914-8. doi: 10.1086/605438.

PMID:
19663597
7.

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.

Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B.

Lancet Glob Health. 2014 Jan;2(1):e51-7. doi: 10.1016/S2214-109X(13)70118-9. Epub 2013 Dec 5.

8.

Oral miltefosine for Indian visceral leishmaniasis.

Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.

N Engl J Med. 2002 Nov 28;347(22):1739-46.

9.
10.

Ambisome plus miltefosine for Indian patients with kala-azar.

Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B.

Trans R Soc Trop Med Hyg. 2011 Feb;105(2):115-7. doi: 10.1016/j.trstmh.2010.10.008. Epub 2010 Dec 3.

PMID:
21129762
11.

Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.

Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J.

Pediatr Infect Dis J. 2003 May;22(5):434-8.

PMID:
12792385
12.

Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

Omollo R, Alexander N, Edwards T, Khalil EA, Younis BM, Abuzaid AA, Wasunna M, Njoroge N, Kinoti D, Kirigi G, Dorlo TP, Ellis S, Balasegaram M, Musa AM.

Trials. 2011 Jun 30;12:166. doi: 10.1186/1745-6215-12-166.

13.

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.

Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, Boelaert M.

PLoS Negl Trop Dis. 2010 Sep 7;4(9). pii: e818. doi: 10.1371/journal.pntd.0000818.

14.

Oral miltefosine for the treatment of Indian visceral leishmaniasis.

Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M.

Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S26-33. Epub 2006 May 26. Review.

PMID:
16730038
15.

Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.

Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J.

Clin Infect Dis. 2012 Aug;55(4):543-50. doi: 10.1093/cid/cis474. Epub 2012 May 9.

PMID:
22573856
16.

A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.

Kumar N, Sinha PK, Pandey K, Verma N, Lal CS, Ranjan A, Verma RB, Das P.

Int J Clin Pharm. 2011 Oct;33(5):726-9. doi: 10.1007/s11096-011-9544-8. Epub 2011 Jul 22.

PMID:
21833710
17.

Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.

Olliaro P, Sundar S.

Trop Med Int Health. 2009 Jan;14(1):88-92. doi: 10.1111/j.1365-3156.2008.02195.x. Epub 2008 Dec 11.

18.

Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.

Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M.

PLoS Negl Trop Dis. 2012;6(6):e1674. doi: 10.1371/journal.pntd.0001674. Epub 2012 Jun 19.

19.

Visceral leishmaniasis: elimination with existing interventions.

Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, Das P, Sinha PK, Rijal S, Mondal D, Zilberstein D, Alvar J.

Lancet Infect Dis. 2011 Apr;11(4):322-5. doi: 10.1016/S1473-3099(10)70320-0. Review.

PMID:
21453873
20.

Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.

Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P.

PLoS Negl Trop Dis. 2014 Sep 18;8(9):e3169. doi: 10.1371/journal.pntd.0003169. eCollection 2014 Sep.

Supplemental Content

Support Center